SCHEMBL14025469

SCHEMBL14025469

CN(Cc1ccccc1)S(=O)(=O)c1ccc(CNC2CCCc3cccnc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.56
HDAC6 Q9UBN7 2/20 0.56
CXCR4 P61073 3/20 0.45
NAMPT P43490 2/20 0.43
LMNA P02545 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPT P10636 2/20 0.42
ALOX12 P18054 1/20 0.42
HTR2C P28335 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025631 0.91 HDAC1 (0.49) HDAC1HDAC6CXCR4LMNAMEN1
SCHEMBL4925551 0.87 HDAC1 (0.54) HDAC1HDAC6CXCR4LMNASMN1; SMN2
SCHEMBL14025185 0.87 HDAC1 (0.54) HDAC1HDAC6CXCR4LMNASMN1; SMN2
SCHEMBL14025462 0.83 HDAC1 (0.60) HDAC1HDAC6CXCR4LMNAALDH1A1
SCHEMBL4887341 0.82 HDAC1 (0.69) HDAC1HDAC6CXCR4ALDH1A1KDM4E
SCHEMBL4562865 0.82 HDAC1 (0.69) HDAC1HDAC6CXCR4ALDH1A1KDM4E
SCHEMBL14045718 0.81 HDAC1 (0.55) HDAC1HDAC6CXCR4KDM4ECYP3A4
SCHEMBL14025497 0.81 HDAC1 (0.59) HDAC1HDAC6CXCR4NAMPTLMNA
SCHEMBL13909820 0.80 HDAC1 (0.76) HDAC1HDAC6CXCR4ALDH1A1KDM4E
SCHEMBL14025642 0.79 HDAC1 (0.48) HDAC1HDAC6CXCR4LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
WO-2008109154-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A HDAC1 703/4885HDAC6 1192/4885CXCR4 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.